Dr. Hui-Ju Lin

 

Speaker：

Dr.  Hui-Ju Lin

Institution：

China Medical University and Hospital

 

Position：

Director of Division, Department of Ophthalmology

Presentation Title：

Atropine and combination therapy

 

Abstract：

    Atropine is a non-selective mAChR antagonist. Animal studies of myopia have shown that atropine effectively prevents the axial elongation that contributes to myopia. Atropine has been shown to inhibit myopia progression in the tree shew, monkey, chick, and mouse. In contrast to the eyes of mammals, chick (avian) eyes consist of striated intraocular muscle; therefore, atropine cannot exert mydriatic or cycloplegic effects in chick eyes, which indicates a nonaccommodative mechanism for atropine in slowing myopia progression. Moreover, human clinical trials have shown the effectiveness of daily atropine administration in reducing myopia progression . However, it has been reported that there are rebound effects after discontinuation of atropine. Even thought after atropine treatment, myopia progression is still significantly lower in the atropine-treated group.

   Nowadays, studies of spectacles or contact lenses that result in large changes in retinal defocus have reported changes in myopia progression. myopic peripheral defocus is hypothesized to slow myopia progression. Somes new studies have reported that soft bifocal or multifocal contact lens or special designer frame glasses can slow myopia progression, and long term clinical trial are in progress.

    Combining the two effective myopia controlling tools in clinical practice is also proposed by many study groups. In this report, we proposed the effects and limitations of the combining myopia treatment.